Capina, Essentialis Merger To Create Rare Disease Firm
Executive Summary
The combined company would advance a diazoxide choline controlled-release daily pill for treating patients with Prader-Willi syndrome through pivotal Phase II/III clinical trialing.
You may also be interested in...
Deal Watch: Sanofi Begins 2017 By Ending Vaccine JV, Completing Swap With Boehringer
At year's end the French pharma also announced a restructuring of its broad diabetes collaboration with South Korea’s Hanmi. In a deal involving two other French companies, OSE out-licensed global development and commercial rights to an IL-7 antagonist to Servier.
Strong PhII data in triglyceride reduction attracts partners to Essentialis
Essentialis Inc. is in discussions with partners and potential acquirers as its moves into Phase III clinical trials for diazoxide choline controlled-release tablets, or DCCR, a drug that may cause dramatic reductions in triglyceride levels for high-risk patients who already are taking cholesterol-lowering medications.
Freshly Funded ImCheck Goes After Gamma Delta T-Cells
ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.
Need a specific report? 1000+ reports available
Buy Reports